The axial spondyloarthritis (axSpA) treatment market comprises medications for managing the signs and symptoms of axSpA. AxSpA causes chronic inflammation of the spine and pelvis. Common symptoms include lower back pain, stiffness in the back, arthritis, and fatigue. Biologics such as TNF inhibitors and IL-17 inhibitors are largely used in treating axSpA patients. However, small molecule drugs that block IL-17 and TNF pathways have emerged as preferred alternatives to biologics due to better efficacy and safety profiles.
The axial spondyloarthritis (axSpA) treatment market is estimated to be valued at USD 6.02 billion in 2024 and is expected to reach USD 10 billion by 2031, growing at a compound annual growth rate (CAGR) of 7.5% from 2024 to 2031.
Key Takeaways
Key players operating in the axial spondyloarthritis treatment market are Amgen, UCB, Eli Lilly and Company, Celgene, and Janssen Biotech. Amgen's Enbrel is a leading TNF inhibitor prescribed to manage both axial and peripheral manifestations of axSpA.
The growing disease prevalence across the globe due to increased awareness and diagnostic capabilities is driving market growth. For example, disease prevalence in the United States is estimated to increase from 0.8% currently to over 1.2% by 2034. Further, technological advancements such as novel drug delivery mechanisms and predictive biomarkers to identify at-risk patients are expected to fuel the market.
Market Trends
The Axial Spondyloarthritis (AXSPA) Treatment Market is witnessing a shift from biologics to oral small molecules owing to better efficacy and tolerability. Drugs like Amgen/UCB's Rinvoq and Eli Lilly's Olumiant have emerged as preferred first-line treatment options over biologics. Another trend is the development of IL-23 inhibitors which prevents inflammation by blocking IL-23 cytokine. AbbVie's risankizumab received FDA approval in 2019 for treating plaque psoriasis and is being evaluated in phase 3 studies for axSpA.
Market Opportunities
Increasing rates of disease misdiagnosis provide significant growth opportunities as proper diagnosis leads to time-bound treatment intervention. Only 50% of patients with axSpA receive an accurate diagnosis within 10 years. Developing innovative diagnostic tools based on genetic, imaging, and molecular testing will aid early diagnosis. This includes biomarkers that accurately differentiate between axial and peripheral spondyloarthritis. Non-TNF biologics and small molecules also present lucrative opportunities with increasing treatment paradigm shifts.
Impact of COVID-19 on Axial Spondyloarthritis (axSpA) Treatment Market Growth
The COVID-19 pandemic has disrupted the normal functioning of healthcare systems across the globe. Resources meant for non-COVID care have been diverted to tackle the rising cases. This has negatively impacted several chronic disease management programs including for axSpA. During the peak of waves, patients avoided or postponed routine visits or procedures due to fear of contracting the virus in hospitals. This led to inadequate disease management and flare-ups. Teleconsultations helped to some extent but were not as effective as in-person visits for this condition. Ensuring uninterrupted access to biologic therapies was challenging initially due to supply chain disruptions.
With vaccination drives underway, the situation is gradually improving in many countries. Healthcare facilities are resuming regular services while following necessary precautions. Greater emphasis is being placed on implementing digital healthcare to enhance virtual care delivery. This includes remote monitoring tools, edtech solutions for patients and provision of certain therapies via mail-order pharmacy. Collaboration between hospital networks is helping patients access multi-disciplinary care nearer home. Payers are also exploring policies to cover telehealth and homecare costs. If these strategies are successful, they could transform long-term management of axSpA in a positive way. However, uncertainty around new variants remains a concern.
Regions with Concentrated Axial Spondyloarthritis (axSpA) Treatment Market Value
North America has traditionally been the region with the highest axSpA treatment spending globally. This is owing to factors like high disease prevalence, widespread health insurance coverage and early uptake of expensive biologic therapies. Countries like the United States account for a major share of the regional market value.
The Asia Pacific region is witnessing fastestannual growth in axSpA treatment expenditure. This is primarily due to rising incomes, growing disease awareness, increased diagnostic capacities and expanding insurance coverage in highly populated nations such as India and China. Low-cost generic versions of drugs are also boosting affordability and accessibility in these markets.
Fastest Growing Regional Market for Axial Spondyloarthritis (axSpA) Treatment
The Asia Pacific region stands out as the fastest growing regional market for axSpA treatment globally. This is projected to continue over the forecast period. Rapid economic development and rising living standards are enabling more patients in Asia Pacific countries to access healthcare and afford treatments. Governments are working to strengthen public insurance schemes like "Ayushman Bharat" in India to reduce out-of-pocket costs. Improved diagnostic infrastructure is aiding early detection and management. Increasing collaboration between global biopharmaceutical companies and local generic players is boosting the availability of affordable therapeutics. Heightened disease awareness campaigns are also facilitating timely seekings of care. With nearly 60% of the world's population, the large patient pool provides immense growth opportunities for axSpA treatment in Asia Pacific.
Get More Insights On- Axial Spondyloarthritis (AXSPA) Treatment Market
Get This Report in Japanese Language: 軸性脊椎関節炎治療市場
Get This Report in Korean Language: 축성 척추관절염치료 시장
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc.
(https://www.linkedin.com/in/ravina-pandya-1a3984191)